[HTML][HTML] Citicoline: pharmacological and clinical review, 2022 update
JJ Secades, P Gareri - Revista de Neurologia, 2022 - ncbi.nlm.nih.gov
This review is based on the previous one published in 2016 (Secades JJ. Citicoline:
pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73) …
pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73) …
PRIMED2 Preclinical Evidence Scoring Tool to Assess Readiness for Translation of Neuroprotection Therapies
Many neuroprotective and other therapies for treatment of acute ischemic stroke have failed
in translation to human studies, indicating a need for more rigorous, multidimensional quality …
in translation to human studies, indicating a need for more rigorous, multidimensional quality …
[PDF][PDF] Current neuroprotective agents in stroke.
T Yanık, B Yanık - Turkish Journal of Physical Medicine & …, 2024 - ftrdergisi.com
What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the
neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life …
neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life …
[HTML][HTML] Citicolina: revisión farmacológica y clínica, actualización 2022
JJ Secades, P Gareri - Revista de Neurología, 2022 - ncbi.nlm.nih.gov
Esta revisión se basa en la publicada en 2016–Secades JJ. Citicolina: revisión
farmacológica y clínica, actualización 2016. Rev Neurol 2016; 63 (Supl 3): S1-S73–, e …
farmacológica y clínica, actualización 2016. Rev Neurol 2016; 63 (Supl 3): S1-S73–, e …